Patent ID: 8309599

Claim:
A method for treating a cellular proliferative disorder in a patient, comprising administering to the patient a therapeutically effective amount of a compound having Formula I, or a pharmaceutically acceptable ester thereof: wherein R 1 and R 8 are independently selected from the group consisting of H, C 1-6 -alkyl, halo(C 1-6 -alkyl), C(O)R 11 , C(O)OR 11 , and C(O)NR 12 R 13 , wherein each R 11 is independently H, C 1-6 -alkyl, or halo(C 1-6 -alkyl), and wherein R 12 and R 13 are selected independently from the group consisting of H, C 1-6 -alkyl, and halo(C 1-6 -alkyl); or R 12 and R 13 , together with the nitrogen atom to which they are bound, form a 5- to 6-membered heterocyclic or heteroaromatic ring; R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from the group consisting of H, C 1-6 -alkyl, and halo(C 1-6 -alkyl); R 7 is selected from the group consisting of H, C 1-6 -alkyl and halo(C 1-6 -alkyl); and R 9 and R 10 are independently selected from the group consisting of H, C 1-6 -alkyl, and C 1-6 -alkyl substituted with one to three groups independently selected from halo, hydroxy, and C 1-6 -alkoxy; R 14 and R 15 are selected independently from the group consisting of halo(C 1-6 -alkyl), C(O)R 11 , F, Cl, NO 2 , and B(OR 11 ) 2 , wherein R 11 is as defined above; or R 14 and R 15 , together with the carbon atom to which they are bound, form an epoxide ring; provided that when R 1 is C(O)CH 3 , R 2 , R 4 , and R 8 are hydrogen, and R 3 , R 5 , R 6 , R 7 , and R 9 are methyl, then R 10 is not hydrogen or OH.